Harmony Biosciences appoints Peter Anastasiou to Board of Directors

Harmony Biosciences Holdings, Inc.

Appointed as Class III director effective November 5, 2023; term expires at 2026 annual meeting.
Board expanded from nine to ten members; Anastasiou deemed independent.
Anastasiou is CEO of Capsida Biotherapeutics and former President of North America at Lundbeck.
Will serve on Compensation Committee; brings CNS and business development expertise.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Peter Anastasiou

Class III director

HRMY · Harmony Biosciences Holdings, Inc.

Effective: 2023-11-05
Filed: November 8, 2023, 6:59 PM ET

appointed Peter Anastasiou as a Class III director of the Company with an initial term expiring at the Company’s 2026 annual meeting of stockholders, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Peter Anastasiou was appointed as Class III director at Harmony Biosciences Holdings, Inc..

Action: appointed
Role: Class III director

Exact text from the filing

appointed Peter Anastasiou as a Class III director of the Company with an initial term expiring at the Company’s 2026 annual meeting of stockholders, effective immediately.

View on SEC.gov

Harmony Biosciences Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-018125

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.